Martin Wermke

Publication Activity (10 Years)

Years Active: 2015-2023
Publications (10 Years): 4

Top Topics

Allogeneic Hematopoietic Stem Cell Transplantation

Top Venues

Journal of clinical oncology : official journal of the American Society of Clinical Oncology

This page only lists publications with an associated author ORCID identifier.

Publications

Filippo de Braud, Christophe Dooms, Rebecca S Heist, Celeste Lebbè, Martin Wermke, Anas Gazzah, Dirk Schadendorf, Piotr Lukasz Rutkowski, Juergen Wolf, Paolo Antonio Ascierto, Ignacio Gil-Bazo, Shumei Kato, Maria Wolodarski, Meredith A McKean, Eva Muñoz Couselo, Martin Sebastian, Armando Santoro, Vesselina Cooke, Luca Manganelli, Kitty Wan, Anil Gaur, Jaeyeon Kim, Giordano Caponigro, Xuân-Mai Couillebault, Helen Evans, Catarina D Campbell, Sumit Basu, Michele Moschetta, Adil I Daud
Initial Evidence for the Efficacy of Naporafenib in Combination With Trametinib in NRAS -Mutant Melanoma: Results From the Expansion Arm of a Phase Ib, Open-Label Study. Journal of clinical oncology : official journal of the American Society of Clinical Oncology (2023)
Marc-Steffen Raab, Yael C Cohen, Schjesvold Fredrik, Kimberly Aardalen, Adwait Oka, Andrew Spencer, Martin Wermke, Anita D Souza, Jonathan L Kaufman, Anna Maria Cafro, Enrique María Ocio, Noriko Doki, Kristin Henson, Gina Trabucco, Ana Carrion, Florent C Bender, Pierre-Eric Juif, Adonai Fessehatsion, Liqiong Fan, Jeffrey P Stonehouse, John W Blankenship, Brian Granda, Serena De Vita, Haihui Lu
Preclinical discovery and initial clinical data of WVT078, a BCMA × CD3 bispecific antibody. Leukemia (2023)
Andrew F Berdel, Leo Ruhnke, Linus Angenendt, Martin Wermke, Christoph Röllig, Jan-Henrik Mikesch, Annika Scheller, Teresa Hemmerle, Mattia Matasci, Klaus Wethmar, Torsten Kessler, Mirjam Gerwing, Daniel Hescheler, Michael Schäfers, Wolfgang Hartmann, Bianca Altvater, Claudia Rossig, Martin Bornhäuser, Georg Lenz, Matthias Stelljes, Bjoern Rueter, Dario Neri, Wolfgang E Berdel, Christoph Schliemann
Using stroma-anchoring cytokines to augment ADCC: a phase 1 trial of F16IL2 and BI 836858 for posttransplant AML relapse. Blood advances 6 (12) (2022)
David P Steensma, Martin Wermke, Virginia M Klimek, Peter L Greenberg, Patricia Font, Rami S Komrokji, Jay Yang, Andrew M Brunner, Hetty E Carraway, Lionel Ades, Aref A Al-Kali, Juan M Alonso-Dominguez, Ana Alfonso-Piérola, Catherine C Coombs, H Joachim Deeg, Ian W Flinn, James M Foran, Guillermo Garcia Manero, Michael B Maris, Malgorzata McMasters, Jean-Baptiste Micol, Jaime Perez De Oteyza, Felicitas Thol, Eunice S Wang, Justin M Watts, Justin Taylor, Richard Stone, Vikram Gourineni, Alyssa J Marino, Huilan Yao, Benoit Destenaves, Xiaobin Yuan, Kun Yu, Sara Dar, Lernik Ohanjanian, Keisuke Kuida, Jianjun Xiao, Catherine Scholz, Antonio Gualberto, Uwe Platzbecker
Phase I First-in-Human Dose Escalation Study of the oral SF3B1 modulator H3B-8800 in myeloid neoplasms. Leukemia 35 (12) (2021)
Martin Wermke, Aylin Camgoz, Maciej Paszkowski-Rogacz, Sebastian Thieme, Malte von Bonin, Andreas Dahl, Uwe Platzbecker, Mirko Theis, Gerhard Ehninger, Sebastian Brenner, Martin Bornhäuser, Frank Buchholz
RNAi profiling of primary human AML cells identifies ROCK1 as a therapeutic target and nominates fasudil as an antileukemic drug. Blood 125 (24) (2015)